Physician profile
Prachi Patel
NPI 1144545849
$11,840.03
in general payments reported to CMS, 2019-2025
55 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $1,111 · 2021: $2,294 · 2022: $2,318 · 2023: $1,887 · 2024: $2,141 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,323.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,691.97 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,371.97 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $1,275.92 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Novo Nordisk INC | $994.35 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $916.71 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $731.95 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $635.48 | 2019-2025 | Evenity, Prolia, Otezla |
| Merck Sharp & Dohme LLC | $483.16 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $419.12 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $241.44 | 2019-2025 | Reblozyl, Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $231.65 | 2021-2024 | Xifaxan |
| Allergan, INC. | $191.29 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $162.44 | 2019-2024 | Trintellix |
| Boston Scientific Corporation | $150.99 | 2023 | Superion Indirect Decompression System |
| Kowa Pharmaceuticals America, INC. | $145.63 | 2020-2023 | Seglentis, Livalo |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prachi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.